Filing Details
- Accession Number:
- 0001209191-14-052015
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-12 20:00:20
- Reporting Period:
- 2014-08-11
- Filing Date:
- 2014-08-12
- Accepted Time:
- 2014-08-12 20:00:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Biosciences Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1302390 | Ward Henry Wolff | C/O Sangamo Biosciences Inc., Point Richmond Tech Cntr, 501 Canal Blvd Richmond CA 94804 | Exec Vp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-08-11 | 8,000 | $7.28 | 228,347 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-08-11 | 8,000 | $14.17 | 220,347 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-08-11 | 2,000 | $14.14 | 218,347 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2014-08-11 | 8,000 | $0.00 | 8,000 | $7.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2017-06-06 | No | 4 | M | Direct |
Footnotes
- Includes 50,000 shares, 30,000 shares, and 35,000 shares subject to RSUs granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
- All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2014.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.71 to $14.44, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.77 to $14.46, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- All shares underlying these options are vested and exercisable immediately.
Billionaire Hedge Funds
